CD2 and CD3 receptor-mediated tolerance: Constraints on T cell activation

Transplantation

Volumn 67, Issue 5, 1999, Pages 741-748

  Punch, Jeffrey D ^a,c   Lin, Jixun ^a   Bluestone, Jeffrey ^b   Bromberg, Jonathan S ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; T LYMPHOCYTE RECEPTOR;

ANIMAL EXPERIMENT; ANTIGEN BINDING; ARTICLE; FEMALE; HEART TRANSPLANTATION; IMMUNOLOGICAL TOLERANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

EID: 0033558975     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199903150-00017     Document Type: Article

References (43)

1. Chavin KD, Qin L, Lin J, Kaplan AJ, Bromberg JS. Anti-CD2 and anti-CD3 monoclonal antibodies synergize to prolong allograft survival with decreased side effects. Transplantation 1993; 55: 901.
2. Chavin KD, Qin L, Lin J, Yagita H, Bromberg JS. Combined anti-CD2 and anti-CD3 receptor monoclonal antibodies induce donor-specific tolerance in a cardiac transplant model. J Immunol 1993; 151: 7249.
3. Pearce NW, Spinelli A, Gurley KE, Hall BM. Specific unresponsiveness in rats with prolonged cardiac allograft survival after treatment with cyclosporine. V. Dependence of CD4+ suppressor cells on the presence of alloantigen and cytokines, including interleukin 2. Transplantation 1993; 55: 374.
4. Nomoto K, Eto M, Yanaga K, Nishimura Y, Maeda T, Nomoto K. Interference with cyclophosphamide-induced skin allograft tolerance by cyclosporin A. J Immunol 1992; 149: 2668.
5. Perico N, Imberti O, Bontempelli M, Remuzzi G. Immunosuppressive therapy abrogates unresponsiveness to renal allograft induced by thymic recognition of donor antigens. J Am Soc Nephrol 1995; 5: 1618.
6. Takai T, Li M, Sylvestre D, Clynes R, Ravetch JV. FcR gamma chain deletion results in pleiotrophic effector cell defects Cell 1994; 76: 519.
7. Altevogt P, Kohl U, Von Hoegen P, Lang E, Schirrmacher V. Antibody 12-15 cross-reacts with mouse Fc gamma receptors and CD2: study of thymus expression, genetic polymorphism and biosynthesis of the CD2 protein. Eur J Immunol 1989; 19: 341.
8. Leo O, Foo M, Sachs DH, Samelson LE, Bluestone JA. Identification of a monoclonal antibody specific for a murine T3 polypeptide. Proc Natl Acad Sci U S A 1987; 84: 1374.
9. Alegre ML, Tso JY, Sattar HA, et al. An anti-murine CD3 monoclonal antibody with a low affinity for Fc gamma receptors suppresses transplantation responses while minimizing acute toxicity and immunogenicity. J Immunol 1995; 155: 1544.
10. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986; 136: 2348.
11. Furth ME, Davis LJ, Fleurdelys B, Scolnick EM. Monoclonal antibodies to the p21 products of the transforming gene of Harvey murine sarcoma virus and of the cellular ras gene family. J Virol 1982; 43: 294.
12. Kubo RT, Born W, Kappler JW, Marrack P, Pigeon M. Characterization of a monoclonal antibody which detects all murine alpha beta T cell receptors. J Immunol 1989; 142: 2736.
13. Unkeless JC. Characterization of a monoclonal antibody directed against mouse macrophage and lymphocyte Fc receptors. J Exp Med 1979; 150: 580.
14. Rozdzial MM, Kubo RT, Turner SL, Finkel TH. Developmental regulation of the TCR zeta-chain. Differential expression and tyrosine phosphorylation of the TCR zeta-chain in resting immature and mature T lymphocytes. J Immunol 1994; 153: 1563.
15. Ortega G, Robb RJ, Shevach EM, Malek TR. The murine IL 2 receptor. I. Monoclonal antibodies that define distinct functional epitopes on activated T cells and react with activated B cells. J Immunol 1984; 133: 1970.
16. Ding Y, Qin L, Yang Q, et al. A novel murine model for the assessment of human CD2-related reagents in vivo. J Immunol 1996; 157: 1863.
17. Chavin KD, Lau HT, Bromberg JS. Prolongation of allograft and xenograft survival in mice by anti-CD2 monoclonal antibodies. Transplantation 1992; 54: 286.
18. Henrickson M, Reid J, Bellet JS, Sawchuk SS, Hirsch R. Comparison of in vivo efficacy and mechanism of action of antimurine monoclonal antibodies directed against TCR alpha beta (H57-597) and CDS (145-2C11). Transplantation 1995; 60: 828.
19. Migita K, Eguchi K, Kawabe Y, Tsukada T, Ichinose Y, Nagataki S. Defective TCR-mediated signaling in anergic T cells. J Immunol 1995; 155: 5083.
20. Wiest DL, Ashe JM, Abe R, Bolen JB, Singer A. TCR activation of ZAP70 is impaired in CD4+CD8+ thymocytes as a consequence of intrathymic interactions that dimmish available p56lck. Immunity 1996; 4: 495.
21. Chavin KD, Qin L, Lin J, Woodward JE, Baliga P, Bromberg JS. Combination anti-CD2 and anti-CD3 monoclonal antibodies induce tolerance while altering interleukin-2, interleukin-4, tumor necrosis factor, and transforming growth factor-beta production. Ann Surg 1993; 218: 492.
22. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989; 7: 145.
23. Dallman MJ, Wood KJ, Hamano K, et al. Cytokines and peripheral tolerance to alloantigen. Immunol Rev 1993; 133: 5.
24. Takeuchi T, Lowry RP, Konieczny B. Heart allografts in murine systems. The differential activation of Th2-like effector cells in peripheral tolerance. Transplantation 1992; 53: 1281.
25. Chavin KD, Qin L, Yon R, Lin J, Yagita H, Bromberg JS. Anti-CD2 mAbs suppress cytotoxic lymphocyte activity by the generation of Th2 suppressor cells and receptor blockade. J Immunol 1994; 152: 372.
26. Punch JD, Qin L, Bishop K, Bromberg JS. Receptor mediated tolerance induction: requirement for IL-4. J Immunol 1998; 161: 1156.
27. Kuchroo VK, Das MP, Brown JA, et al. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 1995; 80: 707.
28. McDonald SA, Palmen MJ, Van Rees EP, MacDonald TT. Characterization of the mucosal cell-mediated immune response in IL-2 knockout mice before and after the onset of colitis. Immunology 1997; 91: 73.
29. Hirsch R, Bluestone JA, DeNenno L, Gress RE. Anti-CD3 F(ab′)2 fragments are immunosuppressive in vivo without evoking either the strong humoral response or morbidity associated with whole mAb. Transplantation 1990; 49: 1117.
30. Hirsch R, Eckhaus M, Auchincloss H Jr, Sachs DH, Bluestone JA. Effects of in vivo administration of anti-T3 monoclonal antibody on T cell function in mice. I. Immunosuppression of transplantation responses. J Immunol 1988; 140: 3766.
31. Hirsch R, Archibald J, Gress RE. Differential T cell hyporesponsiveness induced by in vivo administration of intact or F(ab′)2 fragments of anti-CD3 monoclonal antibody. F(ab′)2 fragments induce a selective T helper dysfunction. J Immunol 1991; 147: 2088.
32. Smith J, Tso J, Clark M, Cole M, Bluestone J. Nonmitogenic anti-CD3 monoclonal antibodies deliver a partial T cell receptor signal and induce clonal anergy. J Exp Med 1997; 185: 1413.
33. Ceuppens JL, Bloemmen FJ, Van Wauwe JP. T cell unresponsiveness to the mitogenic activity of OKT3 antibody results from a deficiency of monocyte Fc gamma receptors for murine IgG2a and inability to cross-link the T3-Ti complex. J Immunol 1985; 135: 388.
34. Vossen AC, Tibbe GJ, Kroos MJ, et al. Fc receptor binding of anti-CD3 monoclonal antibodies is not essential for immunosuppression, but triggers cytokine-related side effects. Eur J Immunol 1995; 25: 1492.
35. Bromberg JS, Chavin KD, Altevogt P, et al. Anti-CD2 monoclonal antibodies alter cell-mediated immunity in vivo. Transplantation 1991; 51: 219.
36. Kurrle R, Schorlemmer HU, Shearman C, et al. Analysis of the immunoregulatory capacity of anti-alpha/beta-TCR and anti-CD3 monoclonal antibodies. Transplant Proc 1991; 23: 272.
37. Kishimoto H, Kubo RT, Yorifuji H, Nakayama T, Asano Y, Tada T. Physical dissociation of the TCR-CD3 complex accompanies receptor ligation. J Exp Med 1995; 182: 1997.
38. Lin J, Yon RW, Chavin KD, et al. Anti-CD2 monoclonal antibody-induced receptor changes: down modulation of cell surface CD2. Transplantation 1995; 59: 1162.
39. Lin J, Chavin KD, Qin L, Ding Y, Bromberg JS. Anti-CD2 monoclonal antibody-induced receptor changes. II. Interaction of CD2 and CDS. Cell Immunol 1996; 167: 249.
40. Ono S, Ohno H, Saito T. Rapid turnover of the CD3ζ chain independent of the TCR-CD3 complex in normal T cells. Immunity 1995; 2: 639.
41. Otsuji M, Kimura Y, Aoe T, Okamoto Y, Saito T. Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 zeta chain of T-cell receptor complex and antigen-specific T-cell responses. Proc Natl Acad Sci U S A 1996; 93: 13119.
42. Madrenas J, Wange RL, Wang JL, Isakov N, Samelson LE, Germain RN. Zeta phosphorylation without ZAP-70 activation induced by TCR antagonists or partial agonists. Science 1995; 267: 515.
43. Sloan-Lancaster J, Shaw AS, Rothbard JB, Allen PM. Partial T cell signaling: altered phospho-zeta and lack of zap70 recruitment in APL-induced T cell anergy. Cell 1994; 79: 913.